MedTrace Logo

A Phase 1 Clinical Trial of Adjuvanted Protein-based HCV Vaccine Candidates (HCV Vaccine Trial)

NCT07237282 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2026-05-06

No results posted yet for this study

Summary

The purpose of this study is to investigate the safety and antibody (germ fighters) response of the experimental (investigational) vaccine against HCV when injected into the arm of healthy adults.

Conditions

  • Hepatitis C

Interventions

BIOLOGICAL

AVIHepC1

Intramuscular injection administered at 0, 4, and 24 weeks.

BIOLOGICAL

Normal Saline

\*Only applicable for double-blinded randomized component of the study. Intramuscular injection administered at 0, 4, and 24 weeks.

Sponsors & Collaborators

  • University of Alberta

    lead OTHER

Principal Investigators

  • Vanessa Meier-Stephenson, MD, PhD · University of Alberta

  • Michael Houghton, PhD · University of Alberta

  • Lorne Tyrrell, MD, PhD · University of Alberta

  • Jordan Feld, MD, MSc · University of Toronto

  • Curtis Cooper, MD, MSc · University of Ottawa

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-08-01
Primary Completion
2027-01-01
Completion
2027-07-01

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07237282 on ClinicalTrials.gov